TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 8473428
Drug: No therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: No therapy (n = 8)
Study: 24633934
Drug: EGb 761
Approvals — FDA: no, EMA: no, PMDA: no
Description: EGb 761 (240 mg daily for 24 weeks)
Study: 18004064
Drug: C.E.R.A. administered
Approvals — FDA: no, EMA: no, PMDA: no
Description: C.E.R.A. administered once every 2 weeks (Q2W) via subcutaneous or intravenous injection
Study: 18004064
Drug: Epoetin administered
Normalized name: Epoetin
DrugBank: Erythropoietin (DB00016)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Epoetin administered at current dose, route, and administration interval (once to three times weekly)
Study: 7724390
Drug: Conventional therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional therapy (digoxin, furosemide, low dose ACE inhibition)
Study: 7724390
Drug: Staged therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Staged therapy (maximal tolerated ACE inhibition, PGE1 therapy, outpatient dobutamine)
Study: 1837942
Drug: Repeated treatment
Normalized name: eicosyl povidone (2 eicosyl branches-repeat)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Repeated treatment (C3)
Study: 7107969
Drug: Penfluridol, maximum
Approvals — FDA: no, EMA: no, PMDA: no
Description: Penfluridol, maximum dose 140 mg per week
Study: 7107969
Drug: Chlorpromazine, maximum
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chlorpromazine, maximum dose 7350 mg per week
Study: 3830763
Drug: Diltiazem 240
Normalized name: diltiazem 240 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diltiazem 240 mg/day (D240)
Study: 3830763
Drug: Diltiazem 360
Normalized name: dilTIAZem 360 mg/24 hours oral tablet, extended release
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diltiazem 360 mg/day (D360)
Study: 3830763
Drug: Nifedipine 120
Normalized name: Nifedipine
DrugBank: Nifedipine (DB01115)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Nifedipine 120 mg/day (N)
Study: 3830763
Drug: Verapamil 480
Approvals — FDA: no, EMA: no, PMDA: no
Description: Verapamil 480 mg/day (V)
Study: 26791678
Drug: Oral prednisolone
Normalized name: prednisolone Oral Solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral prednisolone 0.5 mg kg(‐1) day(‐1) for 10 days
Study: 25623842
Drug: Patient and
Normalized name: JCARH125 CONSISTS OF HUMAN CULTURE EXPANDED GENETICALLY MODIFIED AUTOLOGOUS T CELLS FOR CELL-BASED GENE THERAPY. CD4+ CD8+ T CELLS ARE DERIVED FROM ISOLATED BLOOD OF THE PATIENT AND ARE TRANSDUCED WITH NON-REPLICATIVE SELF-INACTIVATING (SIN) LENTIVIRAL V
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patient and therapy-related factors (age, gender, bruxism, number of prostheses, time since last extraction, smoking, fit of dentures, average denture wearing time, wearing during the night)
Study: 18375896
Drug: Anastrozole (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Anastrozole (1 mg) for 3 months
Study: 18375896
Drug: Letrozole (2.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Letrozole (2.5 mg) for 3 months
Study: 16683008
Drug: Terazosin combined
Approvals — FDA: no, EMA: no, PMDA: no
Description: Terazosin combined with ExMI therapy (group 2)
Study: 16683008
Drug: Terazosin monotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Terazosin monotherapy (group 1)
Study: 27220960
Drug: Sorafenib plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sorafenib plus Erlotinib (400 mg twice daily plus 150 mg once daily)
Study: 27220960
Drug: Sorafenib plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sorafenib plus Placebo (400 mg twice daily plus placebo)
Study: 25100386
Drug: Multiple daily
Normalized name: Multivitamin Oral Tablet [MULTIPLE DAILY W/BETA]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Multiple daily injections (MDI) therapy
Study: 15711353
Drug: Neoadjuvant GNRH
Normalized name: GnRH
DrugBank: Gonadorelin (DB00644)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Neoadjuvant GNRH therapy (1.2 mg per day as nasal spray for 4 weeks)
Study: 14658952
Drug: Risperidone treatment
Normalized name: Risperidone
DrugBank: Risperidone (DB00734)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Risperidone treatment (0.02‐0.06 mg/kg/day)
Study: 10781483
Drug: 0.5 mg.
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.5 mg. kg(‐1) esmolol
Study: 6424926
Drug: MMC plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: MMC plus oral administration of Futraful for 3 months (protocol II, group B)
Study: 6424926
Drug: Intermittent intravenous
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intermittent intravenous injection of a moderate dose of MMC (protocol I, group A)
Study: 6424926
Drug: Bolus intravenous
Normalized name: SET,INFUSION,BOLUS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bolus intravenous injection of MMC (protocol II, group A)
Study: 21216077
Drug: Midazolam +
Normalized name: Midazolam
DrugBank: Midazolam (DB00683)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Midazolam + low-dose ketamine (0.03 mg/kg midazolam + 0.3 mg/kg ketamine + saline)
Study: 21216077
Drug: Midazolam +
Normalized name: Midazolam
DrugBank: Midazolam (DB00683)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Midazolam + placebo (0.03 mg/kg midazolam + 2 mL placebo)
Study: 1599062
Drug: Fentanyl 0.2
Normalized name: fentanyl 0.2 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fentanyl 0.2 mg
Study: 2875594
Drug: Fentanyl 0.1
Normalized name: fentanyl 0.1 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fentanyl 0.1 mg
Study: 6399698
Drug: Adjuvant razoxane
Normalized name: razoxane
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adjuvant razoxane treatment (61 patients)
Study: 6399698
Drug: No further
Approvals — FDA: no, EMA: no, PMDA: no
Description: No further treatment (65 patients)
Study: 30939778
Drug: Music therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Music therapy activities (two different types) added to standard care for 25 weekly sessions
Study: 19678756
Drug: hsCRP level
Normalized name: peanut allergenic extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: hsCRP level > or =5 microg/mL at baseline
Study: 19678756
Drug: IL-6 level
Normalized name: IL-6
DrugBank: Human interleukin-6 (DB15060)
Approvals — FDA: no, EMA: no, PMDA: no
Description: IL-6 level > or =3 pg/mL at baseline
Study: 19678756
Drug: hsCRP level
Normalized name: peanut allergenic extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: hsCRP level > or =5 microg/mL (latest follow-up)
Study: 19678756
Drug: amyloid-A level
Normalized name: .beta.-amyloid protein-(1-6)-peptidylglycylglycyl-L-cysteine-3-(2,5-dioxo-2,5-dihydro-1H-pyrrole-1-yl)-n-(6-((2,5-dioxopyrrolidin-1-yl)oxy)-6-oxohexyl)propanamide-alanine
Approvals — FDA: no, EMA: no, PMDA: no
Description: amyloid-A level > or =6 mg/L (latest follow-up)
Study: 19678756
Drug: IL-6 level
Normalized name: IL-6
DrugBank: Human interleukin-6 (DB15060)
Approvals — FDA: no, EMA: no, PMDA: no
Description: IL-6 level > or =3 pg/mL (latest follow-up)
Study: 17195936
Drug: 7-valent pneumococcal
Normalized name: Streptococcus pneumoniae serotype 10A capsular antigen diphtheria CRM197 protein conjugate vaccine
Approvals — FDA: no, EMA: no, PMDA: no
Description: 7-valent pneumococcal conjugate vaccine followed by the 23-valent pneumococcal polysaccharide vaccine
Study: 17195936
Drug: Hepatitis A
Normalized name: HEPATITIS A
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hepatitis A or B vaccines (Control)
Study: 15504991
Drug: Multiple daily
Normalized name: Multivitamin Oral Tablet [MULTIPLE DAILY W/BETA]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Multiple daily injections (MDII)
Study: 11216970
Drug: Intermittent transdermal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intermittent transdermal nitroglycerin (NTG) 0.6 mg/h
Study: 6777073
Drug: Acetylsalicylic acid
Normalized name: ACETYLSALICYLIC ACID
DrugBank: Acetylsalicylic acid (DB00945)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Acetylsalicylic acid (ASA, 1.5 g/day)
Study: 30380956
Drug: Oblique intradermal
Normalized name: Inonotus obliquus fruiting body
DrugBank: Inonotus obliquus fruiting body (DB14332)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oblique intradermal suture (OIS)
Study: 30380956
Drug: Conventional interrupted
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional interrupted intradermal suture (IS)
Study: 19390223
Drug: Treatment after
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment after 6 weeks
Study: 19390223
Drug: Post-treatment plasma
Normalized name: hydrocortisone
DrugBank: Hydrocortisone succinate (DB14545)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Post-treatment plasma tryptophan concentrations
Study: 19390223
Drug: Post-treatment kynurenine
Normalized name: hydrocortisone
DrugBank: Hydrocortisone succinate (DB14545)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Post-treatment kynurenine concentrations
Study: 9054789
Drug: Intravenous clomipramine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous clomipramine
Study: 9054789
Drug: Oral clomipramine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral clomipramine
Study: 9054789
Drug: Oral clomipramine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral clomipramine after intravenous loading
Study: 8477178
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of oxitropium and fenoterol
Study: 3080920
Drug: Peripheral parenteral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Peripheral parenteral nutrition with antiphlebitic mixture (1000 IU heparin, 5 mg hydrocortisone, and 1.8 mEq sodium hydroxide as a buffer)
Study: 3080920
Drug: Peripheral parenteral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Peripheral parenteral nutrition without antiphlebitic mixture
Study: 22656405
Drug: Dexmedetomidine-Ketamine combination
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dexmedetomidine-Ketamine combination
Study: 22656405
Drug: Dexmedetomidine-Midazolam combination
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dexmedetomidine-Midazolam combination
Study: 20399997
Drug: Enteric-coated flurbiprofen
Normalized name: Flurbiprofen
DrugBank: Flurbiprofen (DB00712)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Enteric-coated flurbiprofen 100-mg tablet (test)
Study: 20399997
Drug: Film-coated immediate-release
Normalized name: IR-3535
Approvals — FDA: no, EMA: no, PMDA: no
Description: Film-coated immediate-release flurbiprofen 100-mg tablet (reference)
Study: 18806023
Drug: Intraoperative low-dose
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Intraoperative low-dose ketamine (bolus dose of 0.5 mg/kg followed by continuous infusion of 4 microg.kg(‐1).min(‐1))
Study: 18806023
Drug: Intraoperative low-dose
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Intraoperative low-dose ketamine
Study: 10084101
Drug: Propofol infusion,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Propofol infusion, 30 mg kg‐1 h‐1
Study: 10084101
Drug: Propofol infusion,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Propofol infusion, 30 mg kg‐1 h‐1 + fentanyl bolus, 2 micrograms kg‐1 i.v.
Study: 7560599
Drug: L-arginine (7
Approvals — FDA: no, EMA: no, PMDA: no
Description: L-arginine (7 g three times daily for 3 days)
Study: 7201089
Drug: Low-dose bromocriptine
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose bromocriptine therapy (average dose, 15 mg per day)
Study: 7201089
Drug: Low-dose bromocriptine
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose bromocriptine therapy (initial dose 1 mg per day with slow escalation)
Study: 3553878
Drug: Low-dose bromocriptine
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose bromocriptine therapy
Study: 23869063
Drug: Intravenous adenosine,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous adenosine, 140 μg·kg(‐1)·min(‐1), during 5 min
Study: 17425616
Drug: Ropivacaine 7.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ropivacaine 7.5 mg/ml plus isotonic sodium chloride solution
Study: 17425616
Drug: Ropivacaine 7.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ropivacaine 7.5 mg/ml plus 100 mg tramadol
Study: 3409620
Drug: Single oral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single oral dose of 200 mg of [15N]glycine as a tracer
Study: 28961980
Drug: Probiotic adjunct
Normalized name: Rezyst Probiotic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Probiotic adjunct therapy
Study: 27144828
Drug: Stem cells
Normalized name: Stem cells, apheresis
Approvals — FDA: no, EMA: no, PMDA: no
Description: Stem cells cultured on beta‐TCP in combination with rh‐PDGF‐BB
Study: 18305079
Drug: GIK (Glucose‐insulin‐potassium)
Normalized name: glucose / potassium chloride
Approvals — FDA: no, EMA: no, PMDA: no
Description: GIK (Glucose‐insulin‐potassium) group
Study: 14665656
Drug: Combination therapy
Normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination therapy (levothyroxine reduced by 50 micro g/d and substituted with liothyronine, 7.5 micro g, taken twice daily for 4 months)
Study: 14665656
Drug: Levothyroxine alone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Levothyroxine alone (usual dose)
Study: 14665656
Drug: Combination therapy
Normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination therapy (levothyroxine plus liothyronine)
Study: 8857434
Drug: Dobutamine infusion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dobutamine infusion (6 mu g kg‐1 min‐1)
Study: 1627200
Drug: 2% sertaconazole
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2% sertaconazole dermatological cream
Study: 1627200
Drug: Excipient of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Excipient of the cream without sertaconazole
Study: 6373426
Drug: Maximized metabolic
Normalized name: Eleutherococcus Senticosus (Rupr. Et Maxim.) Maxim. Root
Approvals — FDA: no, EMA: no, PMDA: no
Description: Maximized metabolic control (multiple insulin injections daily or insulin pumps)
Study: 6373426
Drug: Standard control
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard control (one or more injections of insulin daily)
Study: 30169797
Drug: Culturally targeted
Normalized name: casein, emmental cultured
Approvals — FDA: no, EMA: no, PMDA: no
Description: Culturally targeted Courage to Quit (CTQ-CT) smoking cessation treatment
Study: 21652220
Drug: Doxercalciferol capsules
Normalized name: Doxercalciferol Capsules
DrugBank: Doxercalciferol (DB06410)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Doxercalciferol capsules (conversion factors: 0.5, 1.0, 1.5 times the current paricalcitol dose)
Study: 21652220
Drug: Doxercalciferol capsules
Normalized name: Doxercalciferol Capsules
DrugBank: Doxercalciferol (DB06410)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Doxercalciferol capsules (conversion factors: 1.0, 1.5, 2.0 times the current doxercalciferol injection dose)
Study: 21652220
Drug: Doxercalciferol capsules
Normalized name: Doxercalciferol Capsules
DrugBank: Doxercalciferol (DB06410)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Doxercalciferol capsules
Study: 17554581
Drug: Oral risedronate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral risedronate 2.5 mg/day for 6 months
Study: 17554581
Drug: No osteoactive
Approvals — FDA: no, EMA: no, PMDA: no
Description: No osteoactive drug (Control)
Study: 12584837
Drug: Western medicine
Normalized name: Medicaine Sting
Approvals — FDA: no, EMA: no, PMDA: no
Description: Western medicine combination therapy
Study: 8181590
Drug: Pre-operative intra-arterial
Normalized name: lidocaine
DrugBank: Lidocaine (DB00281)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Pre-operative intra-arterial chemotherapy
Study: 8181590
Drug: More effective
Normalized name: polyurethane-35 (not more than MPA.S at 40 %)
Approvals — FDA: no, EMA: no, PMDA: no
Description: More effective drugs and less demanding regimens
Study: 138560
Drug: Minocycline 50
Normalized name: minocycline 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Minocycline 50 mg twice daily
Study: 138560
Drug: Tetracycline 250
Normalized name: tetracycline 250 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tetracycline 250 mg twice daily
Study: 21738077
Drug: 7.5 g/day
Approvals — FDA: no, EMA: no, PMDA: no
Description: 7.5 g/day TU-025
Study: 21738077
Drug: 12.5 g/day
Approvals — FDA: no, EMA: no, PMDA: no
Description: 12.5 g/day TU-025
Study: 8095127
Drug: Famotidine (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Famotidine (20 mg twice daily)
Study: 8095127
Drug: Nizatidine (150
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nizatidine (150 mg twice daily)
Study: 31538372
Drug: Osmotic-Release Oral
Normalized name: nifedipine
DrugBank: Nifedipine (DB01115)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Osmotic-Release Oral System Methylphenidate (OROS‐MPH)
Study: 19006068
Drug: Real ultrasound
Normalized name: ULTRASOUND
Approvals — FDA: no, EMA: no, PMDA: no
Description: Real ultrasound (US) treatment
Study: 30092205
Drug: Sham ultrasound
Normalized name: ULTRASOUND
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sham ultrasound (US) treatment
Study: 16261462
Drug: Flurbiprofen 50
Normalized name: flurbiprofen 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Flurbiprofen 50 mg followed immediately by propofol LCT 2 mg.kg(‐1)
Study: 16261462
Drug: Flurbiprofen 50
Normalized name: flurbiprofen 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Flurbiprofen 50 mg followed by propofol LCT 2 mg.kg(‐1) 1 min later
Study: 16261462
Drug: 2% Lidocaine
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2% Lidocaine 40 mg followed immediately by propofol LCT 2 mg.kg(‐1)
Study: 16261462
Drug: Propofol LCT
Normalized name: Propofol
DrugBank: Propofol (DB00818)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Propofol LCT 2 mg.kg(‐1) alone
Study: 16261462
Drug: Propofol in
Normalized name: propofol Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Propofol in a mixture of medium‐chain triglyceride (MCT) and LCT 2 mg.kg(‐1)
Study: 11895791
Drug: Anti-Helicobacter pylori
Normalized name: Anti-Helicobacter pylori IgG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Anti-Helicobacter pylori treatment
Study: 10798
Drug: Solcoseryl and
Normalized name: cytarabine and daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Solcoseryl and Proglumide (systematic preventive treatment)
Study: 10798
Drug: No specific
Normalized name: Oregano specific IgE
Approvals — FDA: no, EMA: no, PMDA: no
Description: No specific treatment (Control group)
Study: 30808512
Drug: d‐Nav Insulin
Approvals — FDA: no, EMA: no, PMDA: no
Description: d‐Nav Insulin Guidance System with health‐care professional support
Study: 28072863
Drug: 30mg/kg of
Approvals — FDA: no, EMA: no, PMDA: no
Description: 30mg/kg of oral azithromycin
Study: 28072863
Drug: 50,000 units/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 50,000 units/kg of intramuscular benzathine penicillin
Study: 26264718
Drug: Hydrocortisone (HC)
Normalized name: Hydrocortisone
DrugBank: Hydrocortisone succinate (DB14545)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Hydrocortisone (HC) >20 mg/day
Study: 26264718
Drug: Hydrocortisone (HC)
Normalized name: Hydrocortisone
DrugBank: Hydrocortisone succinate (DB14545)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Hydrocortisone (HC) (all doses)
Study: 26264718
Drug: Hydrocortisone (HC)
Normalized name: Hydrocortisone
DrugBank: Hydrocortisone succinate (DB14545)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Hydrocortisone (HC) ≤20 mg/day
Study: 23794107
Drug: tolcapone (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: tolcapone (100 mg three times a day for 1 day and then 200 mg three times a day for 6 days)
Study: 9863076
Drug: Shuxuening (SXN)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Shuxuening (SXN) 120 mg three times daily
Study: 8181219
Drug: tiapride (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: tiapride (200 mg/die)
Study: 23838501
Drug: Topical diltiazem
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical diltiazem gel (2ml of 2% topical diltiazem gel)
Study: 14664471
Drug: Glatiramer acetate
Normalized name: Glatiramer Acetate
DrugBank: Glatiramer (DB05259)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Glatiramer acetate (GA), 20 mg daily subcutaneous injections
Study: 11094039
Drug: SR90107A/ORG31540 (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: SR90107A/ORG31540 (5 mg once daily)
Study: 11094039
Drug: SR90107A/ORG31540 (7.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: SR90107A/ORG31540 (7.5 mg once daily)
Study: 11094039
Drug: SR90107A/ORG31540 (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: SR90107A/ORG31540 (10 mg once daily)
Study: 11094039
Drug: Dalteparin (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dalteparin (100 IU/kg twice daily)
Study: 8747098
Drug: Diet-oriented treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diet-oriented treatment
Study: 6624809
Drug: Picenadol (LY
Approvals — FDA: no, EMA: no, PMDA: no
Description: Picenadol (LY 150720), 25 mg
Study: 510179
Drug: Meperidine, 100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Meperidine, 100 mg
Study: 29716398
Drug: Context of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Context of treatment (research vs community)
Study: 20812879
Drug: Pregabalin (300
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pregabalin (300 and 450 mg/day)
Study: 15868384
Drug: Aprinocarsen (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aprinocarsen (2 mg/kg continuous iv infusion on days 1-14, every 21 days) + Gemcitabine (1250 mg/m2 on days 1 and 8) + Cisplatin (80 mg/m2 on day 1)
Study: 15868384
Drug: Gemcitabine (1250
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gemcitabine (1250 mg/m2 on days 1 and 8) + Cisplatin (80 mg/m2 on day 1)
Study: 10506601
Drug: Induction therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Induction therapy with AFM
Study: 8966143
Drug: Captopril (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Captopril (50 mg once daily)
Study: 27069360
Drug: Puer tea
Approvals — FDA: no, EMA: no, PMDA: no
Description: Puer tea extract (PTE) 3 g/day
Study: 25043321
Drug: Basic body
Normalized name: Basic Fuchsin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Basic body awareness therapy (BBAT) (10 weeks)
Study: 22483196
Drug: Learning therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Learning therapy (reading aloud and solving simple calculations)
Study: 18094894
Drug: Oral contraceptive
Normalized name: VCF Contraceptive
DrugBank: Nonoxynol-9 (DB06804)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral contraceptive with placebo (levonorgestrel and ethinyl estradiol)
Study: 18094894
Drug: Oral contraceptive
Normalized name: VCF Contraceptive
DrugBank: Nonoxynol-9 (DB06804)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral contraceptive with estriol (levonorgestrel and ethinyl estradiol)
Study: 9917438
Drug: Amoxicillin (750
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amoxicillin (750 mg once daily)